Loading…
Employees: 81
Size Lexicon Pharmaceuticals (LXRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $792M, the 2403rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $1.78 on 6 Nov 2026.
Performance Over six months the shares fell 11.0%, against -8.0% for the median peer and -1.1% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue fell 29.0% over the last twelve months (peer median +2.7%); the operating margin is -131.4% (peer median 10.1%).
Valuation It trades at 15.9× enterprise value to sales against a peer median of 2.4× (4th most expensive of 19).
Capital Return on invested capital runs 109.8 points below its cost of capital (10.0% WACC).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $41.5M | $49.8M | $31.1M | $1.20M | $139,000 |
| Revenue growth | — | +60% | +2,481% | +766% | — |
| Gross profit | $40.6M | $48.9M | $29.9M | $565,000 | -$288,000 |
| EBITDA | -$54.0M | -$48.3M | -$184M | -$171M | -$100M |
| Net income | -$61.1M | -$50.3M | -$200M | -$177M | -$102M |
| Free cash flow | -$65.0M | -$67.9M | -$181M | -$162M | -$90.2M |
| Capital expenditure | $0 | $0 | $1.03M | $470,000 | $1.33M |
| Total debt | $59.2M | $62.2M | $106M | $106M | $55.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LXRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.1% | -3.6% | 9th highest of 20 |
| 6-month return | -11.0% | -8.0% | 9th lowest of 20 |
| Distance from 52-week high | -33.6% | -30.4% | 9th lowest of 20 |
| Revenue growth (TTM) | -29.0% | +2.7% | 2nd lowest of 19 |
| Operating margin | -131.4% | 10.1% | 4th lowest of 19 |
| EV / Sales | 15.9× | 2.4× | 4th most expensive of 19 |
| ROIC minus cost of capital | -109.8 pp | +1.6 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | 15.9× | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | 849.2× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | 2.5× | 0.2% | +0.5% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 1.9× | -1.1% | +26.1% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 2.3× | -7.0% | +20.3% |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | 1.4× | -1.4% | 0.0% |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 4.2× | 16.5% | -8.7% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 1.9× | 9.5% | +17.7% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | 4.2× | 18.2% | +2.1% |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | 0.8× | n/a | n/a |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | 45.8× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | 0.9× | -3.0% | -0.8% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 4.3× | 11.5% | +11.3% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | 5.7× | 10.7% | -1.4% |
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 2.0× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 1.1× | -6.3% | +10.6% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $771M | -29% | -16% | 0% | 0.4× | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $825M | -8% | +2% | 20% | 3.2× | -1.8% | +2.6% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $825M | -54% | +68% | -170% | 32.3× | n/a | n/a |